Free Trial
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel
NASDAQ:PTGX

Protagonist Therapeutics Q3 2026 Earnings Date & Estimates

Protagonist Therapeutics logo
$138.49 -6.39 (-4.41%)
Closing price 04:00 PM Eastern
Extended Trading
$138.55 +0.06 (+0.04%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for November 2, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Protagonist Therapeutics in Q3 2026

Protagonist Therapeutics is expected to post earnings of $2.38 per share on revenue of $241.46 million. In the same quarter a year earlier Protagonist Therapeutics reported -$0.62 per share on revenue of $4.71 million. Protagonist Therapeutics last reported on August 5, 2026, posting $2.29 per share and beating the $2.27 consensus estimate. Protagonist Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$2.38
Expected Revenue
$241.46 million
Prior-Year EPS
-$0.62
Prior-Year Revenue
$4.71 million
Expected Revenue Growth
+5,024.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$2.29 (Beat by +$0.02)
Last Quarter Revenue
$213.48 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Protagonist Therapeutics Q3 2026 Earnings FAQ

Protagonist Therapeutics (NASDAQ:PTGX) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Protagonist Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 2, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Protagonist Therapeutics to post earnings of $2.38 per share for Q3 2026.

The consensus revenue estimate for Protagonist Therapeutics is $241.46 million for Q3 2026.

Protagonist Therapeutics Earnings Headlines

Head to Head Contrast: Protagonist Therapeutics (NASDAQ:PTGX) & AbCellera Biologics (NASDAQ:ABCL)
October 13 at 5:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114293
UBS initiates coverage of Protagonist Therapeutics with buy rating
October 12 at 2:43 PM  |  msn.comhttps://www.msn.com/en-us/money/other/ubs-initiates-coverage-of-protagonist-therapeutics-with-buy-rating/ar-AA2e4AxY
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
October 13 at 1:00 AM  |  Base Camp Trading (Ad)
Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology
October 12 at 2:43 PM  |  msn.comhttps://www.msn.com/en-us/money/general/nektar-protagonist-shattuck-are-leerink-top-picks-in-emerging-immunology/ar-AA2e5cZO
UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target
October 12 at 9:43 AM  |  marketscreener.comM
Protagonist Therapeutics' (PTGX) Outperform Rating Reaffirmed at Leerink Partners
October 12 at 9:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31110617
See More Protagonist Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email.

About Protagonist Therapeutics

Protagonist Therapeutics (NASDAQ:PTGX) (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based medicines for chronic immune-mediated and hematologic diseases. The company uses its proprietary technology platform to design peptides intended to selectively interact with disease-relevant biological targets.

Protagonist’s pipeline includes icotrokinra, formerly known as JNJ-2113, an investigational oral peptide that selectively targets the interleukin-23 receptor. The program is being developed through a collaboration with Johnson & Johnson for conditions including psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The company is also developing rusfertide, formerly known as PTG-300, an investigational hepcidin mimetic designed to regulate iron availability and treat polycythemia vera and other myeloproliferative neoplasms. Rusfertide is being advanced through a collaboration with Takeda.

Founded in 2006, Protagonist is headquartered in Newark, New Jersey, and conducts research and clinical development activities through collaborations and partnerships serving international markets. The company is led by Dinesh V. Patel, who serves as president and chief executive officer.

View Protagonist Therapeutics Profile
Earnings Tools